Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · IEX Real-Time Price · USD
41.47
+0.08 (0.19%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 123 employees as of December 31, 2022. The number of employees increased by 28 or 29.47% compared to the previous year.
Employees
123
Change (1Y)
28
Growth (1Y)
29.47%
Revenue / Employee
n/a
Profits / Employee
-$2,092,675
Market Cap
4.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 123 | 28 | 29.47% |
Dec 31, 2021 | 95 | 48 | 102.13% |
Dec 31, 2020 | 47 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Alkermes | 2,100 |
Guardant Health | 1,779 |
Ultragenyx Pharmaceutical | 1,276 |
Inspire Medical Systems | 1,011 |
ImmunityBio | 628 |
Axsome Therapeutics | 545 |
DYN News
- 4 weeks ago - Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run? - Forbes
- 2 months ago - Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints - GlobeNewsWire